Fludara

(Fludarabine)

ApprovedSmall molecule

Fludarabine is used to treat certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL) and some lymphomas. It works by damaging the DNA of cancer cells, causing them to die.[2] Fludara is currently approved and in use across 208 indications[4].[1]

Fludara is one of 2029 small molecule programs targeting Follicular Lymphoma. It is currently in Approved.

208

Indications

1,057

Total Trials

Active Trials

2,028

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Follicular LymphomaActive, not recruiting

Aplastic AnemiaRecruiting

Sickle Cell DiseaseRecruiting

Diffuse Large B-Cell LymphomaRecruiting

MelanomaRecruiting

Prostate CancerTerminated

Autoimmune DiseaseEnrolling by invitation

MemoryWithdrawn

Myelodysplastic SyndromesTerminated

Rheumatoid ArthritisRecruiting

Follicular LymphomaPhase 3

Active, not recruiting

Aplastic AnemiaPhase 2

Recruiting

Sickle Cell DiseasePhase 2

Recruiting

Diffuse Large B-Cell LymphomaPhase 2

Recruiting

MelanomaPhase 2

Recruiting

Prostate CancerPhase 1

Terminated

Autoimmune DiseasePhase 1

Enrolling by invitation

MemoryPhase 2

Withdrawn

Myelodysplastic SyndromesPhase 2

Terminated

Rheumatoid ArthritisPhase 1

Recruiting

Showing 10 of 208 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fludara

Sanofi

Approved

10 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Study completion

NCT03983850

Phase 1Active, not recruiting

Patients With Solid Tumors

NCT02869217

Phase 1Recruiting

Renal Impairment

NCT05534620

Phase 1Recruiting

Hematopoietic Cell Transplantation

NCT04024761

Phase 1/2Recruiting

Lung Cancer

NCT06538012

Phase 1/2Recruiting

Rectum Cancer

NCT06530303

Clinical

Trials by Indication[1]

Lymphoma15 trials

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT03105336·159 enrolled

Tandem Auto-Allo Transplant for Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01181271·42 enrolled

Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)

Active, not recruiting·—·Phase 1·NCT02287311·38 enrolled

Show 12 more trials

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Unknown status·MMaisonneuve-Rosemont Hospital·Phase 1/2·NCT00807196·20 enrolled

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Recruiting·—·Phase 1/2·NCT06323525·30 enrolled

Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Terminated· Gilead logo

Gilead·Phase 1·NCT04314843·6 enrolled

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01434472·20 enrolled

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00117156·26 enrolled

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Recruiting·KKeimyung University Dongsan Medical Center·Phase 2·NCT02859402·34 enrolled

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 1·NCT07024147·20 enrolled

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT04074746·45 enrolled

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT05590221·20 enrolled

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Recruiting·—·Phase 1/2·NCT07009002·30 enrolled

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT04160195·2 enrolled

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00577993·210 enrolled

Chronic Lymphocytic Leukemia11 trials

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Completed· Roche logo

Roche·Phase 3·NCT04285567·166 enrolled

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche·Phase 2·NCT00545714·86 enrolled

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00254410·30 enrolled

Show 8 more trials

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00899431·39 enrolled

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193466·40 enrolled

Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Terminated· Gilead logo

Gilead·Phase 1·NCT03624036·16 enrolled

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

Completed·SSteven E. Coutre·Phase 2·NCT00230282·25 enrolled

Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

Completed·UUniversity of Pittsburgh·Phase 2·NCT00280241·65 enrolled

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00262782·877 enrolled

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05244070·5 enrolled

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00381004·60 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation6 trials

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00429026·40 enrolled

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·UUniversity of California, Irvine·Phase 2·NCT06028828·60 enrolled

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

Unknown status·—·Phase 1/2·NCT02014506·30 enrolled

Show 3 more trials

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT04626726·50 enrolled

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Completed·—·Phase 1/2·NCT00056966·24 enrolled

Allogeneic Stem Cell Transplantation5 trials

Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

Completed·—·Phase 2/3·NCT01019876·38 enrolled

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 2·NCT00683046·204 enrolled

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06807606·35 enrolled

Show 2 more trials

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Terminated·—·Phase 1/2·NCT00056979·2 enrolled

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01518153·16 enrolled

Metastatic Melanoma5 trials

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT00003552

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01319565·102 enrolled

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00314106·26 enrolled

Show 2 more trials

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01993719·33 enrolled

TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment

Terminated·TThe Christie NHS Foundation Trust·Phase 2·NCT01995344·2 enrolled

105 more indications

Multiple Myeloma5 trials

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT03380039·6 enrolled

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03502577·19 enrolled

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03958656·13 enrolled

Show 2 more trials

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00948922·124 enrolled

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01758328·29 enrolled

Stem Cell Transplant5 trials

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Completed·—·Phase 1/2·NCT00048412·40 enrolled

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Terminated·—·Phase 1/2·NCT00579111·4 enrolled

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled

Show 2 more trials

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active, not recruiting·DDiane George·Phase 1/2·NCT02061800·14 enrolled

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00051311·62 enrolled

Acute Myeloid Leukemia5 trials

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 1·NCT05712278·7 enrolled

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·PPETHEMA Foundation·Phase 3·NCT02319135·289 enrolled

Show 2 more trials

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00053014·5 enrolled

Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00488709·47 enrolled

Hematologic Malignancies4 trials

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02199041·24 enrolled

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02566304·35 enrolled

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Terminated·UUniversity of Virginia·Phase 2·NCT01622556·6 enrolled

Show 1 more trial

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Completed·UUniversity Hospital Tuebingen·Phase 1/2·NCT00202917·61 enrolled

Fanconi Anemia4 trials

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Recruiting·PPorteus, Matthew, MD·Phase 1/2·NCT04784052·18 enrolled

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03600909·3 enrolled

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Recruiting·—·Phase 2·NCT02143830·70 enrolled

Show 1 more trial

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00595127·21 enrolled

Metastatic Cancer3 trials

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT02153905·3 enrolled

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04536922

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02111850·21 enrolled

Myelodysplastic Syndrome3 trials

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Terminated·WWashington University School of Medicine·Phase 1/2·NCT01898793·89 enrolled

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01019317·151 enrolled

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02212561·19 enrolled

Severe Aplastic Anemia3 trials

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Completed·MM.D. Anderson Cancer Center·N/A·NCT00427336·9 enrolled

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06412497·60 enrolled

A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT01187017·1 enrolled

Sickle Cell Disease3 trials

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Completed·—·Phase 1·NCT02065596·4 enrolled

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Terminated·WWashington University School of Medicine·Phase 1·NCT02678143·1 enrolled

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Active, not recruiting·—·Phase 2·NCT00408447·53 enrolled

Autoimmune Disease3 trials

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

Enrolling by invitation· Gilead logo

Gilead·Phase 1·NCT07038447·52 enrolled

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting·FFate Therapeutics·Phase 1·NCT06308978·244 enrolled

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Recruiting·IIRIS Research and Development, LLC·Phase 1·NCT06581562·30 enrolled

Follicular Lymphoma3 trials

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06313996

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Completed·UUniversity of Liverpool·Phase 3·NCT01303887·680 enrolled

Randomized Study for Patients With Follicular Lymphoma Needing Treatment

Completed·LLymphoma Study Association·Phase 3·NCT00140569·400 enrolled

Transplantation3 trials

Completed·MMassachusetts General Hospital·Phase 2·NCT00133367·32 enrolled

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

Pilot Study of Unrelated Cord Blood Transplantation

Terminated·KKing's College Hospital NHS Trust·Phase 2·NCT00916045·40 enrolled

Acute Leukemia2 trials

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05521087

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Terminated· Roche logo

Roche·Phase 1/2·NCT04029688·38 enrolled

Recurrent or Refractory2 trials

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Completed·SStanford University·Phase 1·NCT04088890·52 enrolled

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Active, not recruiting·LLoyola University·Phase 1·NCT04214886·24 enrolled

Graft Versus Host Disease2 trials

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Terminated·NNantes University Hospital·Phase 2·NCT03263767·47 enrolled

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04127721

Trial2 trials

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Completed·CCancer Research UK·Phase 1·NCT02761915·17 enrolled

Randomised Trial in Waldenstrom's Macroglobulinaemia

Completed·UUniversity College, London·Phase 2·NCT01592981·60 enrolled

Leukemia2 trials

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Completed·—·Phase 1·NCT01020539·18 enrolled

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Completed·PPETHEMA Foundation·Phase 1/2·NCT01435343·55 enrolled

Peripheral Blood Stem Cell Transplantation2 trials

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615144·1 enrolled

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

Completed·—·Phase 2·NCT00282282·31 enrolled

R/R AML2 trials

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Recruiting·AARCE Therapeutics, Inc.·Phase 1/2·NCT06680752·49 enrolled

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

Completed·SSumithira Vasu·Phase 1·NCT04220684·19 enrolled

Treatment2 trials

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Not yet recruiting·PPETHEMA Foundation··NCT06175702·150 enrolled

Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05578378·32 enrolled

T Cell Therapy2 trials

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Recruiting·—·Phase 1/2·NCT06838832·30 enrolled

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Completed·VVanderbilt-Ingram Cancer Center·Phase 4·NCT05108805·25 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Terminated· Gilead logo

Gilead·Phase 1·NCT03139370·16 enrolled

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Terminated·MMustang Bio·Phase 1/2·NCT04109482·3 enrolled

Acute Lymphoblastic Leukemia2 trials

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 2·NCT03860844·67 enrolled

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Completed·TTCR2 Therapeutics·Phase 1/2·NCT04323657·6 enrolled

B-cell Malignancies2 trials

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Terminated·UUniversity of Alabama at Birmingham·Phase 2/3·NCT00714259·5 enrolled

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Active, not recruiting·SStanford University·Phase 1·NCT04088864·10 enrolled

Ovarian Cancer2 trials

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06305299·27 enrolled

TIL Therapy for Metastatic Ovarian Cancer

Completed·IInge Marie Svane·Phase 1·NCT02482090·6 enrolled

Bone Marrow Transplantation2 trials

Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

Completed·UUniversity of California, San Francisco··NCT01316549·67 enrolled

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04959175·320 enrolled

Hematological Diseases2 trials

Allo HSCT Using RIC for Hematological Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02661035·156 enrolled

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01962636·200 enrolled

Memory2 trials

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Withdrawn·WWashington University School of Medicine·Phase 2·NCT04893915

Active, not recruiting·—·Phase 1·NCT01953900·26 enrolled

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00698009·1 enrolled

Systemic Lupus Erythematosus2 trials

Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT02080195·1 enrolled

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Not yet recruiting·EEdiGene Inc.·Phase 1·NCT06373991·12 enrolled

Malignant Disease1 trial

Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038857·29 enrolled

Immunotherapy1 trial

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02280811·12 enrolled

Advanced1 trial

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Active, not recruiting·TTCR2 Therapeutics·Phase 1/2·NCT03907852·57 enrolled

Chronic Granulomatous Disease1 trial

Completed·—·Phase 2·NCT00578643·15 enrolled

Lenalidomide1 trial

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT00738829·45 enrolled

Thyroid Cancer1 trial

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02390739

Refractory AML1 trial

Epigenetic Reprogramming in Relapse/Refractory AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT03263936·37 enrolled

Lymphoid Malignancies1 trial

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Withdrawn·SShanghai Pudong Hospital·Phase 1·NCT05513612

MDS1 trial

Busulfan and Fludarabine in Patients With AML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00502905·200 enrolled

Toxicity1 trial

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05293509

Acute Lymphoblastic Leukaemia1 trial

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT03821610·242 enrolled

Efficacy1 trial

Efficacy of G-CSF-Priming in Elderly AML Patients

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199147·250 enrolled

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Withdrawn·—·Phase 1·NCT06572631

Acute Myeloblastic Leukaemia1 trial

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

Unknown status·HHannover Medical School·Phase 2/3·NCT00209833·200 enrolled

Scleroderma1 trial

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

Terminated·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1·NCT00040651·15 enrolled

Epstein Barr Virus1 trial

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

Unknown status·YYang Yang·Phase 1/2·NCT03044743·20 enrolled

Immunodeficiency1 trial

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Terminated·—·Phase 1/2·NCT00579137·3 enrolled

Myeloid1 trial

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

Completed·—·Phase 1·NCT02916979·20 enrolled

Myelodysplastic Syndromes1 trial

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00480987·27 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT05633615·396 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05624554·300 enrolled

Primary Peritoneal Cancer1 trial

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT02118285·2 enrolled

Donor1 trial

URMC Related Haplo-identical Donor BMT

Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled

CLL1 trial

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Completed·FFrench Innovative Leukemia Organisation·Phase 3·NCT00564512·178 enrolled

Adenocarcinoma1 trial

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated·CCelularity Incorporated·Phase 1/2·NCT05207722·1 enrolled

Growth1 trial

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Recruiting·AAcepodia Biotech, Inc.·Phase 1·NCT06415487·30 enrolled

Synovial Sarcoma1 trial

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Completed· GSK logo

GSK·Phase 1·NCT01343043·50 enrolled

Patients With Solid Tumors1 trial

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT02869217·22 enrolled

Kidney Cancer1 trial

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00091611·3 enrolled

Glioblastoma Multiforme1 trial

A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)

Terminated·MMilton S. Hershey Medical Center·Phase 1·NCT00990496·25 enrolled

Conditioning1 trial

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Completed·NNorthside Hospital, Inc.·Phase 2·NCT02581007·25 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Terminated·—·Phase 2·NCT00040417·15 enrolled

T Cells1 trial

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT05114837

Relapsed or Refractory Hematologic Malignancies1 trial

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02718755

Hemoglobinopathies1 trial

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Completed·NNorthwell Health·Phase 1/2·NCT02435901·29 enrolled

Richter's Syndrome1 trial

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00452374·48 enrolled

Renal Impairment1 trial

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Recruiting·Mmedac GmbH·Phase 1·NCT05534620·36 enrolled

Liposarcoma1 trial

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Completed· GSK logo

GSK·Phase 2·NCT02992743·23 enrolled

Bone Marrow Failure1 trial

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04232085·27 enrolled

Advanced Solid Tumors1 trial

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Unknown status·BBGI, China·Phase 1·NCT05798546·21 enrolled

APL1 trial

IS-free Treg HaploHCT

Recruiting·—·Phase 1·NCT04678401·30 enrolled

Mantle Cell Lymphoma1 trial

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT05155215·68 enrolled

GvHD1 trial

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Terminated·IIndiana University·N/A·NCT00594308·10 enrolled

Hematologic Malignancy1 trial

Terminated·—·Phase 2·NCT01500161·1 enrolled

CAR T Cell Therapy1 trial

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Unknown status·PPeng Liu·Phase 1·NCT03706547·20 enrolled

Gastrointestinal1 trial

Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab

Completed·—·Phase 1·NCT02845999·9 enrolled

B-cell acute lymphoblastic leukemia1 trial

QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Recruiting·—·Phase 1·NCT06056752·10 enrolled

Lung Cancer1 trial

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06538012·85 enrolled

Suicide1 trial

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01875237·3 enrolled

Refractory1 trial

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Unknown status·HHenan Cancer Hospital·Phase 1/2·NCT03263208·20 enrolled

Rheumatoid Arthritis1 trial

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

Completed·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT00001677·40 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recruiting·JJohn Reneau·Phase 1·NCT04848064·12 enrolled

Kidney Transplant1 trial

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06056102·20 enrolled

Anemia1 trial

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Completed·UUniversity of Minnesota·Phase 1/2·NCT00005898·30 enrolled

Cold Agglutinin Disease1 trial

Therapy for Chronic Cold Agglutinin Disease

Completed·UUniversity of Bergen·Phase 2·NCT00373594·30 enrolled

Hematopoietic Cell Transplantation1 trial

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Recruiting·—·Phase 1·NCT04024761·50 enrolled

Non-Small Cell Lung Cancer1 trial

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03215810·20 enrolled

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Aplastic Anemia1 trial

Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)

Completed·MMedical College of Wisconsin·Phase 2·NCT02918292·32 enrolled

Relapsed/Refractory1 trial

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT03016377·17 enrolled

Rectum Cancer1 trial

Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06530303·85 enrolled

Hematologic Cancer1 trial

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT04083170·1 enrolled

Relapse1 trial

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA

Active, not recruiting·—·Phase 1·NCT02379520·32 enrolled

Stem Cell1 trial

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06193486·30 enrolled

Maintenance Therapy1 trial

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Active, not recruiting·JJacqueline Garcia, MD·Phase 1·NCT03613532·102 enrolled

Cell Therapy1 trial

Natural Killer(NK) Cell Therapy in r/r AML

Unknown status·ZZhejiang University·Phase 1·NCT05665114·18 enrolled

Phase II1 trial

Phase II Trial GA101 Inbrutinib B CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT02666898·135 enrolled

Phase 11 trial

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Active, not recruiting·—·Phase 1/2·NCT02158091·32 enrolled

Infusion1 trial

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT02274506

Papilloma1 trial

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01585428·29 enrolled

Unspecified2 trials

Cellular Therapy With Cord Blood Cells

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00427557·31 enrolled

Optimizing PTCy Dose and Timing

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT03983850·105 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 18, 1991

FLUDARA

NDA NDA020038

Sep 21, 2007

FLUDARABINE PHOSPHATE

NDA NDA022137

Dec 18, 2008

OFORTA

NDA NDA022273

Sources

References

[1]
ClinicalTrials.gov — 1057 trial records for Fludarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Fludara drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Fludarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Fludarabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022273). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi

Fludara

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Lymphoma15 trials

Chronic Lymphocytic Leukemia11 trials

Allogeneic Hematopoietic Stem Cell Transplantation6 trials

Allogeneic Stem Cell Transplantation5 trials

Metastatic Melanoma5 trials

Multiple Myeloma5 trials

Stem Cell Transplant5 trials

Acute Myeloid Leukemia5 trials

Hematologic Malignancies4 trials

Fanconi Anemia4 trials

Metastatic Cancer3 trials

Myelodysplastic Syndrome3 trials

Severe Aplastic Anemia3 trials

Sickle Cell Disease3 trials

Autoimmune Disease3 trials

Follicular Lymphoma3 trials

Transplantation3 trials

Acute Leukemia2 trials

Recurrent or Refractory2 trials

Graft Versus Host Disease2 trials

Trial2 trials

Leukemia2 trials

Peripheral Blood Stem Cell Transplantation2 trials

R/R AML2 trials

Treatment2 trials

T Cell Therapy2 trials

Safety and Efficacy2 trials

Acute Lymphoblastic Leukemia2 trials

B-cell Malignancies2 trials

Ovarian Cancer2 trials

Bone Marrow Transplantation2 trials

Hematological Diseases2 trials

Memory2 trials

Relapsed or Refractory2 trials

AML2 trials

Neuroblastoma2 trials

Systemic Lupus Erythematosus2 trials

Malignant Disease1 trial

Immunotherapy1 trial

Advanced1 trial

Chronic Granulomatous Disease1 trial

Lenalidomide1 trial

Thyroid Cancer1 trial

Refractory AML1 trial

Lymphoid Malignancies1 trial

MDS1 trial

Toxicity1 trial

Acute Lymphoblastic Leukaemia1 trial

Efficacy1 trial

Mesenchymal Stem Cells1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Acute Myeloblastic Leukaemia1 trial

Scleroderma1 trial

Epstein Barr Virus1 trial

Immunodeficiency1 trial

Myeloid1 trial

Myelodysplastic Syndromes1 trial

Diffuse Large B-Cell Lymphoma1 trial

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Primary Peritoneal Cancer1 trial

Donor1 trial

CLL1 trial

Adenocarcinoma1 trial

Growth1 trial

Synovial Sarcoma1 trial

Patients With Solid Tumors1 trial

Kidney Cancer1 trial

Glioblastoma Multiforme1 trial

Conditioning1 trial

Stem Cell Transplantation1 trial

Bone Marrow Transplant1 trial

T Cells1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

Hemoglobinopathies1 trial